This week, Abiomed announced a class I recall of Impella heart pumps; the FDA released new device sterilization standards; and Boston Scientific planned a $140m new campus in Minnesota.

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.

metaMe Health CEO and ex-Takeda executive Tim Rudolphi and partner firm Indegene’s senior vice president Marut Setia discuss with Scrip plans for the FDA-authorized, gut-directed hypnotherapy Regulora, including an openness to outcomes-based pricing and the wider go-to-market strategy.